Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer.

Ther Adv Med Oncol · 2021 · PMC8488507 · PMID 34616492

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Results were considered nominally significant at a 5% level without controlling for multiplicity.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.